A Correlative Study of Metabolic Syndrome and Coronary Artery Disease among Type 2 Diabetics And Non-Diabetics by Vadivukkarasi, T
  
A DISSERTATION 
 
ON 
 
A CORRELATIVE STUDY OF METABOLIC 
SYNDROME AND CORONARY ARTERY 
DISEASE AMONG TYPE 2 DIABETICS           
AND NON-DIABETICS 
 
Submitted to 
THE TAMILNADU DR. M. G. R. MEDICAL 
UNIVERSITY 
CHENNAI 
 
 
with fulfillment of the regulations 
for the award of 
M.D DEGREE IN GENERAL MEDICINE 
BRANCH I 
 
 
GOVERNMENT MOHAN KUMARAMANGALAM 
             MEDICAL COLLEGE SALEM 
                         
MARCH – 2007  
  
CERTIFICATE 
 
This is to certify that the Dissertation entitled             
“A CORRELATIVE STUDY OF METABOLIC SYNDROME 
AND CORONARY ARTERY DISEASE AMONG TYPE2 
DIABETICS AND NON-DIABETICS” is a record of bonafide 
research work done by Dr.T.VADIVUKKARASI, Post 
graduate in the Department of General Medicine Govt. 
Mohan Kumaramangalam Medical College, Salem, under 
my supervision and guidance and the conclusions are her 
own. This is being submitted in fulfillment of the rules and 
regulations for the degree of M.D (General Medicine) 
Examination in March 2007. 
 
 
 
H.O.D       Unit Chief 
 
 
 
 
 
 
 
 
 
DEAN 
 
  
DECLARATION 
 
 I solemnly declare that this dissertation                       
“A CORRELATIVE STUDY OF METABOLIC SYNDROME 
AND CORONARY ARTERY DISEASE AMONG TYPE2 
DIABETICS AND NON-DIABETICS” was prepared by me 
at Government Mohan Kumaramangalam Medical College 
and Hospital, Salem under the guidance and supervision of 
Prof. Dr. K. Sathyamoorthy M.D, Professor of medicine, 
Govt. Mohan Kumaramangalam Medical College and 
Hospital Salem. 
 
 This dissertation is submitted to The Tamil Nadu               
Dr. M.G.R. Medical University, Chennai in fulfillment of the 
university regulations for the award of the degree of           
M.D. Branch 1 General Medicine. 
 
Place: Salem 
Date :                      
                                 (Dr. T.VADIVUKKARASI) 
        
               
  
ACKNOWLEDGEMENT 
 I take this opportunity to thank my teachers, 
Prof.K.Sathyamoorthy, HOD. Dept. of Medicine, 
Prof.Dandapani, Registrar, Dept. of Medicine and 
Prof.T.Sundarajan, for their encouragement and guidance. 
 I thank The Dean, Dr.Anusuya, MD., DGO., 
GMKMCH, Salem for her spontaneous admittance towards 
the conductance of this study in hospital premises. 
 I thank Dr.Anuradha, M.D., DM (Cardiology), HOD 
Cardiology for her guidance.  
 I also thank Dr.Evangeline Nesa Rathnabai, M.D., 
(Biochemistry), HOD, Biochemistry and Dr.Priya, M.D., 
(Biochemistry), Asst. Professor Bio-chemistry for their 
kindness provided in doing this study. 
 I am deeply indebted to Mr.Subramaniam for 
extending his lab assistance. 
  
 I thank my unit Assistants Dr.Suresh Kanna, M.D., 
Dr.Manjula, M.D., Dr.S.R.Subramaniam, Dr.A.Ravi, 
Dr.Pachiappan, who helped me in my hard times. 
 I thank all the patients who participated in the study. 
 I thank my parents and my husband for the support 
given by them during this study. 
 Above all, the Almighty who poured his wonderful 
blessings from above. With god incharge, I believe that 
everything will work out for the best. 
  
INDEX 
 
S.No. Topic Page 
No. 
1. INTRODUCTION 1 
2. AIM OF THE STUDY 4 
3. REVIEW OF LITERATURE 5 
4. MATERIALS AND METHODS 22 
5. OBSERVATIONS AND RESULTS 28 
6. DISCUSSION 48 
7. SUMMARY AND CONCLUSIONS 55 
 BIBLIOGRAPHY  
 ABBREVIATIONS  
 MASTER CHART  
 PROFORMA  
 
 1
INTRODUCTION 
 
 Over the decades, there has been a phenomenal rise in the 
incidence of CAD in India. The quantum rise in the prevalence of CAD 
in urban-India is very likely due to changes in lifestyle and food habits. 
 The twin epidemics of Diabetes mellitus and Heart disease are a 
major threat to the well being as well as the economic development of 
India. It is believed that a combination of factors, genetic and 
environmental including newer risk factors like the metabolic syndrome 
and hyper coagulability in addition to traditional risk factors like 
smoking, hypertension and hyper cholesterolemia is the culprit behind 
the explosive rise in the incidence of these diseases. [1] 
 WHO shows that India has 32 million diabetic subjects and this is 
projected to increase to 100 million by the year 2035. 
 It is obvious that we need to put in place preventive measures. 
But before instituiting preventive measures we must know who is at risk 
for these diseases. Here comes Metabolic syndrome, a deadly 
combination of Hypertension, Diabetes mellitus, Dyslipidemia and 
abdominal obesity. 
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 The concept of the metabolic syndrome is perhaps the most 
significant development in the management of cardiovascular diseases 
in the last 10 years. 
 Avogaro and creapaldi first described the syndrome over 40 years 
ago. [2] 
 The importance of the concept for everyday clinical practice was 
only highlighted in 1988, however, when Gerald Reaven drew attention 
to a constellation of features associated with coronary heart disease. He 
suggested that Insulin resistance played a central etiologic role in 
providing a link between these components.[3] 
 In subsequent decades it has become evident that syndrome X is a 
cluster of risk factors for Diabetes and cardiovascular disease. 
 The prevalence of metabolic syndrome has varied markedly 
between different studies, most likely because of lack of accepted 
criteria. 
 In 1998 WHO proposed a unifying definition for the syndrome 
and chose to call it the “metabolic syndrome” rather than the Insulin 
resistance syndrome. 
 3
 This name was chosen primarily because it was not considered 
established that Insulin resistance was the cause of all the components of 
the syndrome. 
 Present study was undertaken with the aim of studying the 
prevalence of metabolic syndrome among Type 2 Diabetics and Non-
Diabetics and its influence upon the occurrence of Coronary Artery 
disease. 
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AIMS AND OBJECTIVES 
 
1) To study the prevalence of metabolic syndrome among Type 2 
Diabetics and Non-Diabetics. 
2) To study the sex distribution and Age distribution in patients with 
metabolic syndrome among Type 2 Diabetics and Non-Diabetics. 
3) To study the influence of metabolic syndrome on risk of CAD 
among Type 2 Diabetics and Non-Diabetics. 
4) To study the risk of individual components of Metabolic 
syndrome on occurrence of CAD among Type 2 Diabetics and 
Non-Diabetics. 
5) To study the influence of glycemic control in CAD among Type2 
Diabetics. 
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REVIEW OF LITERATURE 
 
 The prevalence of Coronary Artery disease is directly 
proportional to the prevalence of its risk factors. Risk factors for CAD 
can be divided into lipid factors and Non-lipid factors. 
 Non-lipid factors include 
- Diabetes mellitus  
- Hypertension 
- Smoking 
- Positive family history 
- Gender, Body mass Index, Physical activity 
Other emerging risk factors include, 
- Thrombogenic factors 
- Chlamydial infections 
- Helicobacterial infections. 
But in South Asians, the high incidence and the malignant course of 
CAD cannot be explained by these traditional risk factors. Here the 
metabolic syndrome dominates the scene. Many of the lipid 
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abnormalities present in this community can be attributed to this 
syndrome. [4] 
HISTORICAL BACKGROUND OF METABOLIC SYNDROME 
1923 - Kylin described the clustering of hypertension,   
  hyperglycaemia, hyperuricaemia. 
1936 - Himsworth noted that a large number of Diabetic patients 
  were insulin resistant. Yalow and Berson devised the first 
  radio immunoassay for insulin in 1959 and used it to show 
  that Insulin resistance was accompanied by   
  hyperinsulinaemia. 
1988 - Reaven rejuvenated and immortalized their facts in his  
  Banting memorial lecture-“The Role of Insulin Resistance 
  in Human disease”. 
1999 - WHO Definition was proposed 
2001 - NCEP guidelines were proposed 
The term metabolic syndrome has been used variously by disparate 
organizations to connote different entities.[5] 
 WHO have used this term to indicate a state of Insulin resistance 
with pervasive dysmetabolism. 
 WHO definition of this syndrome includes. 
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1) Impaired glucose regulation/Diabetes mellitus  
2) Insulin resistance 
3) Raised Arterial pressure >160/90 
4) Raised plasma triglyceride >150 mg/dl and/or low HDL 
cholesterol <35 mg/dl in men or<39 mg/dl in women. 
5) Central obesity [Males: waist to hip ratio >0.9 females: waist 
to hip ratio >0.85] and / or Body mass index >30 kg/m2 
6) Microalbuminuria 
To satisfy the criterion of metabolic syndrome, a patient needed 
to have either criterion one or two positive along with atleast two of the 
four remaining criteria.[6] 
Conceptualization of the metabolic syndrome as a unique, high 
risk Cardiovascular state, as defined by the National cholesterol 
Education program [NCEP], is gaining acceptance as the basis for 
diagnosing the metabolic syndrome [7]. 
The NCEP definition is based on clustering of multiple metabolic 
abnormalities associated with Insulin resistance but does not require a 
measure of Insulin sensitivity i.e., no requirement exists for an 
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experimental demonstration of Insulin resistance or a measurement of 
impaired insulin mediated glucose disposal.[5] 
Definition of Metabolic syndrome – NCEP ATP III guidelines 
Risk factor      Defining level 
Abdominal obesity 
 Men      > 40 inches 
 Women     > 35 inches 
Triglycerides      ≥ 150 mg/dl 
HDL cholesterol 
 Men      < 40 mg/dl 
 Women     < 50 mg/dl 
Blood pressure     ≥ 130/85 mm of Hg 
Fasting glucose      ≥ 110mg/dl 
Any 3-5 symptoms is suggestive of metabolic syndrome. 
The metabolic syndrome, as defined by the NCEP, is not to be 
confused with the Insulin resistance syndrome although such resistance 
is likely but not always in patients with metabolic syndrome. Based on 
the criteria of the NCEP, the diagnosis of metabolic syndrome is highly 
effective in predicting excess cardiovascular risk. Lakka et al in the 
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kuoppio study showed the impact of metabolic syndrome on 
cardiovascular mortality-which was three fold increase.[8] 
It is important to emphasize, however, that although a common 
etiologic thread may account for the association between the 
components of the syndrome, large ethnic differences exist, both in the 
pattern of risk factors and in the manifestations of the syndrome. For 
example, based on the prevalence of obesity and hypertension, it was 
surprising that there were fewer cardiovascular deaths in North 
American Samoans, compared with Americans of European origin. Less 
risk of Cardiovascular death has been reported in Nauruans and pimas 
when compared with Caucasians, based on obesity and Type 2 Diabetes 
mellitus in these populations.[9] 
In Diabetic African Americans, HDL was much higher and TGL 
was much lower when compared with Caucasians. 
In south Indians where CAD is more prevalent, where the 
syndrome components are of a far more classical nature, same criteria 
cannot be used, because most of us would not meet the waist 
circumference defined in NCEP guidelines. 
The international Diabetic federation has defined central obesity 
as waist circumference in males>90 cms in females > 80 cms 
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• TGL ≥ 150 mg% 
• HDL –  males ≤ 40 mg% 
Females ≤ 50 mg% 
• Blood pressure ≥ 130/85 mm of Hg 
• Fasting plasma glucose ≥ 100 mg% / known Diabetic 
3 to 5 positive criteria is required for the diagnosis. 
This criteria should be used as a model to diagnose metabolic 
syndrome which are suitable to our own people. [10] 
ETIOLOGY 
 Both genetic and environmental factors contribute to the 
development of metabolic syndrome. Various hypothesis have been put 
forth. 
1. Thrifty genotype hypothesis 
 Need [11] put forth this theory. He suggested how 
hyperinsulinemia provided a survival advantage in primitive humans in 
“feast and famine”. The post prandial hyperinsulinemia, reduces 
glycosuria and promotes glucose storage and hence survive fast. 
Whereas the same in modern humans leads to Insulin resistance, β-cell 
failure and Type2 Diabetes mellitus. 
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2. Reaven Cahill hypothesis [‘Not so’ thrifty genotype] 
 Reaven [12] based on cahill’s work has interpreted that muscle 
Insulin resistance supplied brain its substrate by 
1) Increased serum glucose because of reduced muscle uptake. 
2) Release of fatty acids by adipose tissue. But the same 
hypothesis lead to Insulin resistance, β-cell failure and Type2 
Diabetes mellitus in modern humans. 
3. Thrifty phenotype hypothesis 
 This hypothesis suggests that metabolic syndrome is the result of 
the suboptimal environment during intra-uterine period and neonatal 
period. 
 Barker [13] studied data from Britain and showed that with 
increasing birth weight the death rate from heart disease fell and 
metabolic syndrome diagnosis progressively decreased. 
4. Common soil hypothesis 
 Stern suggested that atherosclerosis and Diabetes share same 
genetic and environmental antecedents [14] stern was the one who 
categorised the metabolic syndrome components and that they would 
predict future arteriosclerosis.[15] 
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PATHOPHYSIOLOGY OF CAD IN RELATION TO 
COMPONENTS OF METABOLIC SYNDROME:- 
1. HYPERGLYCAEMIA AND CAD 
 Increase in plasma glucose levels have long been recognised as a 
risk factor for CAD. Plasma glucose has been shown to have a 
continuous gradient relationship with CAD both in the diabetic range 
and in the non-diabetic range.[16] 
 DECODE study [17] proposed post-prandial hyperglycaemia to 
be associated with CAD occurrence than fasting hyperglycemia. 
Whereas, in the special analysis of the NHANES III database, there was 
a fivefold increase in the incidence of retinopathy in the fasting glucose 
interval of 110 to 119 mg/dl compared with the interval of 100 to 109 
mg/dl. 
 Similarly the UKPDS used a fasting glucose level of 108 mg/dl to 
diagnose diabetes and encountered a 21% incidence of retinopathy in 
their newly diagnosed patients. [18] Thus much lower levels of fasting 
hyperglycemia may be associated with milder degrees of type 2 diabetes 
than the level currently used for the diagnosis of type 2 Diabetes mellitus 
[126 mg/dl]. The metabolic syndrome may overlap, to a variably greater 
extent, the diagnosis of type 2 diabetes and may ultimately be replaced 
by a more aggressive diagnosis of this disorder. 
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2. HYPERTENSION AND CAD 
 Studies have shown that an increase in BP by 5mm of Hg is 
associated with 34% increase in risk for CAD [19] and this applies to 
diabetics as well as Normoglycaemic individuals.  
 Whereas a reduction in BP by 5 mm of Hg can lead to significant 
reduction in cardiovascular mortality [20] uncomplicated hypertension 
without any risk factors should be controlled to less than 130/85 mm of 
Hg; complicated hypertension like Diabetes, CAD, chronic kidney 
disease, the target BP should be below 120/80 mm of Hg.[20] 
 Presence of left ventricular hypertrophy directly correlates with 
cardio vascular mortality and morbidity which can be regressed by 
Angiotensin converting enzyme inhibitors [esp. perindopril] and 
Indapamide. In hypertensives the entire cardiovascular mortality and 
morbidity rests on control of endothelial dysfunction which can be 
corrected with drugs like Angiotensin converting enzyme Inhibitors, 
Nebivolol, folic acid supplements, statins and calcium channel 
blockers.[21,22] 
 Tight glycaemic control in hypertensives prevent cardiovascular 
morbidity and mortality. The co-existence of hyperlipidemia and 
hypertension also play a role in the pathogenesis of CAD. If there are 
additional risk factors like Diabetes mellitus, chronic kidney disease, 
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cerebro-vascular accident, irrespective of the lipid levels, statins have to 
be introduced to control the LDL levels to below 70 mg%. [23] 
3. OBESITY AND CAD 
 Obesity was not a feature of the syndrome originally described by 
Reaven. It was Vague who first described in 1956 that Regional 
adiposity plays a greater role in the development of diabetes, Impaired 
glucose tolerance and atherosclerosis.[24] Larson et al demonstrated a 
significant association between waist-hip ratio and incidence of 
cardiovascular disease.[25] 
 Framingham study showed waist circumference was predictive of 
cardiovascular disease [26] waist circumference is measured at a point 
halfway between the lower costal margin and the superior iliacs. 
Despres and colleagues have shown that waist circumference alone 
provides a good measurement of visceral fat and that metabolic 
complications may first be observed with circumference of ≥100cm.[27] 
 This subcutaneous fat accounts for 80% of total adipose tissue, 
yet the intraperitoneal fat accounts for 6-20% of total adipose tissue 
volume. The latter is the most metabolically active and deleterious to 
health and is strongly associated with insulin resistance. 
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Insulin Resistance of Adipose tissue [28,29,30] 
Increased lipolysis 
Increased in Non-esterified fatty acids 
Increase in VLDL (Triglyceride) 
Lipoprotein lipase of Adipose tissue activity is depressed in Insulin 
resistance leading to reduced Triglyceride removal from VLDL resulting 
in hypertriglyceridemia. Also Insulin resistance leads to reduced 
apolipoprotein-B degradation resulting in formation of small, dense 
atherogenic LDL. 
4. DYSLIPIDEMIA AND CAD 
Individuals with Insulin resistance have a characteristic lipid 
disturbance: 
Elevated VLDL Triglycerides, decreased plasma HDL. And 
plasma LDL levels are quantitatively within the same range as 
individuals with no insulin resistance, but qualitatively different in that 
the LDL particles are smaller and more dense. 
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Increase in Insulin resistance at the level of Adipose tissue 
↓ 
↑in the release of Free fatty acids (FFA) 
and ↓ in the uptake of FFA 
↓ 
excessive flux of FFA s into the liver 
↓ 
↑in VLDL secretion by the liver  
and ↑ synthesis of apolipoprotein C-III synthesis which reduce 
degradation of VLDL 
↓ 
VLDL exchange their triglycerides for cholesterol esters of HDL 
by the action of cholesterol ester transfer protein (CETP) 
↓ 
Triglyceride rich HDL, acted upon by Hepatic lipase 
↓ 
Apo A1 is released and HDL size is reduced 
↓ 
HDL is lost through the kidney. Thus HDL particle clearance is 
increased. 
 Several large prospective observational studies and intervention 
trials show a strong positive relationship between raised TGL and CAD- 
a dose response relationship. Hypertriglyceridemia is an independent 
 17
risk factor for CAD when it is associated with low HDL and / or raised 
LDL.[31] 
 There is an inverse relation between HDL and CAD. The 
Framingham heart study has established that individuals with HDL 
cholesterol <35 mg/dl have 8 times increase in CAD incidence than 
those with HDL >65 mg/dl. 
The mechanism by which HDL confers decreased risk for CAD is 
poorly understood. 
1. They indirectly initiate TGL catabolism and remnant removal.  
2. They accept free cholesterol from cells and play a key role in 
cholesterol transport. 
HDL2 is large and more cholesterol rich than HDL3 and hence is more 
anti-atherogenic. 
 Women have significantly high plasma levels of HDL2 than men, 
giving the cardioprotection seen in premenopausal women. 
 As LDL is the major carrier of cholesterol, its levels are directly 
proportional to the risk of CAD. It is that LDL composition that 
influences CAD risk [32]. Based on electrophoretic pattern LDL has 
been divided into large or fluffy LDL (Pattern A) and small dense LDL 
(Pattern B). Pattern B is associated with a threefold increase in the risk 
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of MI. Pattern B individuals are more resistant to treatment than those 
with pattern A. 
 Lipoprotein (a) [LP(a)] is an independent risk factor for CAD 
[33]. The level of LP (a) is genetically determined, occurs as a complex 
between LDL and plasma apolipoprotein (a). It is ten times more 
atherogenic than LDL. Levels >30 mg/dl is associated with CAD risk. 
Screening for Lp (a) levels routinely is not recommended. Yet they 
should be measured in  (1) patients with elevated LDL levels 
(2) Premature CAD 
(3) Family history of CAD 
The only therapeutic option to lower Lp (a) is Niacin, alone or in 
combination with colestipol hydrochloride at 3-4 g/day. 
 Upon review of information on HDL and CAD, a causal 
relationship exists between them. For TGL the data are mixed. 
The pattern of Dyslipidemia and CAD in Indians [4] 
1. CAD is present with relatively lower levels of lipids and 
lipoproteins. 
2. Raised TGL and low-HDL cholesterol occurs commonly.  
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3. Dysmetabolic syndrome X of Insulin resistance is more 
commonly associated with a high risk. 
4. Lp (a) plays a very dominant role. 
5. Elevated plasminogen Activator inhibitor-1 
6. Atherogenic phenotype pattern B. 
In south Asians, the high incidence of CAD that occurs 
prematurely and runs a malignant course cannot be explained by the 
traditional risk factors. Insulin resistance and the Dysmetabolic 
syndrome X dominate the scene. Many of the risk factors of CAD in 
their community can be attributed to this syndrome. 
Clinical and therapeutic implications of Metabolic syndrome 
The usefulness of this syndrome are: 
1. Patients with any one of the components of the syndrome are at 
risk of having the other conditions, for which they should be 
screened. 
2. Reduction in Cardiovascular risk in such a patient will require 
treatment of all risk factors, and it is important to recognize that 
treatment of one may sometimes lead to detrimental changes in 
another. For example, treating hypertension with thiazide 
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diuretics may lead to carbohydrate dysmetabolism and 
hyperlipidemia. 
3. Obesity aggravates the syndrome and therefore adiposity, in 
particular visceral adiposity should be included in patient 
assessment. 
Two important studies have shown direct correlation of these risk 
factors with the extent of underlying atherosclerotic lesions in young 
individuals. [34] Thus it has been argued that intervention should begin 
in childhood. The benefits of alteration in lifestyle, such as cessation of 
smoking, physical exercise and attention to weight, however are 
important interventions in both the young and adult population. 
Weight loss is associated with marked improvement in metabolic 
and physiologic profiles. We have lifestyle modifications in the form of 
diet and exercise (5 or more sessions/week of approximately 3-5 
miles/day consisting of a brisk walking pace of 3-4 miles/hour has good 
insulin sensitizing benefits) and pharmacological interventions that 
include, Orlistat and sibutramine for those failing life style 
modifications. [5] 
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Treatment of Dyslipidemia include [5] 
1. Statins: Produce 30% to 40% reduction of LDL mass. 
2. Fibric acid derivatives: for lowering TGL and raising HDL 
3. Nicotinic acid: for raising HDL when TGL is not markedly 
elevated. 
Treatment of hypertension [5] 
 Because endothelial dysfunction is an important part of metabolic 
syndrome ACE inhibitors and Aldosterone receptor antagonists are 
useful in improving hypertension and relieving endothelial dysfunction. 
Treatment of impaired carbohydrate tolerance [5] 
 The impaired fasting glucose of metabolic syndrome may or may 
not be accompanied by Impaired glucose tolerance. Impaired glucose 
tolerance is associated with Insulin resistance, Impaired fasting glucose 
may or may not be associated with Insulin resistance-it is associated 
with declining B-cell function. Studies have demonstrated a clear benefit 
of metformin and Thiazolidinediones in the treatment of Impaired 
glucose tolerance. Here in patients with Impaired fasting glucose, who 
fail to adhere to lifestyle modifications, chemoprevention of Diabetes 
with metformin and Thiazolidinediones can be warranted. 
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MATERIALS AND METHODS 
 
 This study is an observational study conducted in a major public 
hospital from June 2004 to September 2006 and included total of 70 
Diabetics and 50 Non-diabetics. The reference population is Tamil 
speaking population belonging to lower and low middle socio-economic 
status attending government hospitals. The experimental population 
were all >40yrs and taken from Diabetic outpatients department, general 
OPD and general wards. 
Inclusion criteria 
1. Males and females >40 yrs attending OPD for other illness 
[for Non-Diabetic population] 
2. Known Diabetics on treatment/not on treatment; Newly 
detected Diabetics according to American Diabetes 
Association guidelines. 
Exclusion criteria 
1. Smokers, alcoholics 
2. Age <40 yrs 
3. Type1 Diabetics 
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4. Diseases that affect lipid profile like hypothyroidsm, 
cushing’s syndrome, chronic Renal failure, Nephrotic 
syndrome, and those with TGL levels >350 mg /dl 
5. Family history of premature CAD [< 45 years in first degree 
male relatives and < 55 years in female relatives] 
6. Patients with Valvular heart disease, primary 
cardiomyopathies. 
7. Pregnant ladies and those who are on oral contraceptives. 
8. Those who are on Drugs affecting lipid profile (Thiazides and 
Metformin and Tniazolidinediones β-blockers, statins, 
Nicotinic acid, fibric acid derivatives). 
 A standardised health questionnaire was used covering the 
subject’s past medical history, including current and previous 
medications, information about other diseases-Hypertension, CAD, 
stroke, physical activity family history of Diabetes mellitus and CAD. 
Physical examination included- 
1. Two Blood pressure recordings obtained from right arm of 
patients, in sitting position, after 30 min of rest and at 5 min 
interval and then mean value was calculated. 
 24
2. Waist circumference was measured with a soft tape on standing 
subjects, midway between the lowest rib and iliac crest. 
Investigations 
1. Fasting blood samples were drawn for measurement of blood 
glucose, Hb AIC, serum lipid profile  
2. Routine 12 lead Electrocardiogram 
3. 2-D echocardiogram  
were performed in each and every patient. 
The NCEP ATP III guidelines published in 2001 recommend that 
plasma levels of Triglyceride, HDL-C to be measured after a 12 hour 
overnight fast. [Harrison’s principle of Internal Medicine 16th edition, 
Page. 2295]. 
In our lab, the total cholesterol and TGL were measured 
enzymatically and then the cholesterol in the supernatant was taken after 
precipitation of apo B-containing lipoproteins to determine HDL-C. 
LDL-C is estimated using the following equation: 
LDL-C= Total Cholesterol - ⎟⎠
⎞⎜⎝
⎛
5
desTriglyceri -HDL-C 
VLDL-C=
5
TGLPlasma  
 This formula is reasonably accurate if test results are obtained on 
fasting plasma and if the TGL level < 350 mg/dl 
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Defining Criteria 
Metabolic syndrome-NCEP, ATP III guidelines 
        Risk factor      Defining level 
1. Abdominal obesity 
 Men    waist circumference >40 inches 
 Women   waist circumference>35 inches 
2. Triglycerides   >150 mg/dl 
3. HDL Cholesterol 
 Men    <40 mg/dl 
 Women   < 50 mg/dl 
4. Blood pressure   ≥ 130/85 mm of Hg 
5. Fasting glucose   ≥ 110 mg/dl 
 Since the defining level for Abdominal obesity was very high for an 
average Indian, we considered the International Diabetic Federation, 2005, 
definition of obesity, for our experimental population which was ≥ 90 cm for 
men and ≥ 80 cm for women. IDF also includes “Diabetic” status in 5th 
component mentioned above. In our study, we also considered the 5th 
component as fasting glucose > 110 mg/dl or Diabetic state together. Any 3-5 
symptoms positivity was considered as metabolic syndrome.  
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Diabetes mellitus-ADA guidelines [Harrison’s Principles of Internal 
medicine – 16th Edition] 
Symptoms of Diabetes mellitus + Random blood sugar ≥ 200 
mg/dl 
(Or) 
Fasting plama glucose ≥ 126 mg/dl 
(or) 
Post-prandial glucose ≥ 200 mg/dl after 2 hours of an oral 
glucose level of 75g. 
CAD definition 
- History of Nitroglycerine use 
- Experiencing typical angina 
- Previous Myocardial Infarction 
Presence of any one of the three, was the minimum 
requirement. And this was Validated against 
ECG changes 
and  
2D Echo 
Presence of Q waves and ST-T changes in ECG were taken as positive 
for CAD. This was confirmed by Regional wall motion abnormalities in 
2D Echo which was the gold standard finding for CAD in this study. 
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Glycaemic control 
 HbA1, C  < 7% is good 
   > 7% is poor 
Data was collected, compiled and presented in tabular columns and 
graphic forms and analysed subsequently. Chi-square test was used as 
the statistical test for significance with ‘P’ value of <0.05 as significant. 
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OBSERVATIONS AND RESULTS 
 
TABLE – 1  
PREVALENCE OF METABOLIC SYNDROME IN TYPE2 
DIABETES – MELLITUS 
METABOLIC SYNDROME NO. OF CASES PERCENTAGE
PRESENT 49 70% 
ABSENT 21 30% 
TOTAL 70 100% 
 Out of total 70 patients of Type2 Diabetes mellitus, metabolic 
syndrome was seen in 49 (70%) patients. Thus the prevalence of 
Metabolic syndrome in type 2 Diabetes Mellitus is 70%. 
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TABLE – 2  
SEX DISTRIBUTION OF METABOLIC SYNDROME 
AMONG TYPE2 DIABETICS 
METABOLIC SYNDROME MALE (n=45) FEMALE (n=25)
PRESENT 32 (71.11%) 17 (68%) 
ABSENT 13 (28.88%) 08 (32%) 
TOTAL 45 (100%) 25 (100%) 
 Out of total 45 male patients of type2 Diabetics, Metabolic 
syndrom was seen in 32 patients (71.11%) while almost similar 
prevalence (68%) was found in female patients of type2 Diabetics. 
 Thus there was no significant difference found between 
prevalence of Metabolic syndrome in males and females with type2 
Diabetics. 
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TABLE – 3 
AGE DISTRIBUTION OF METABOLIC SYNDROME 
AMONG TYPE 2 DIABETICS 
METABOLIC SYNDROME 
AGE-GROUP 
PRESENT ABSENT 
TOTAL 
40-50 11 (61.11%) 07 (38.88%) 18 
51-60 25 (71.42%) 10 (28.57%) 35 
≥ 61 13 (76.47) 04 (23.52%) 17 
In patients between the age group of 40 and 50 yrs Metabolic 
syndrome was present in 61.11% of patients. 
 In those between 51 and 60 yrs it was present in 71.42%. 
 In those ≥ 61 yrs it was present in 76.47%. 
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TABLE – 4 
PREVALENCE OF CORONARY ARTERY DISEASE IN 
RELATION WITH GLYCAEMIC CONTROL IN TYPE 2 
DIABETES MELLITUS 
GLYCAEMIC 
CONTROL 
NO. OF 
CASES WITH 
CAD 
NO. OF 
CASES 
WITHOUT 
CAD 
TOTAL 
GOOD (n=17) 03 (17.64%) 14 (82.35%) 17 
POOR (n=53) 20 (37.73%) 33 (62.26%) 53 
TOTAL 23 47 70 
 Coronary Artery disease was found in 37.73% patients of poor 
glycaemic control. Thus although there appears to be increase risk of 
CAD in patients with poor glycaemic control, by applying chi – square 
test, it was found that there was no statistically significant                           
(P value > 0.05) association between risk of CAD and glycaemic 
control. 
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TABLE – 5  
PREVALENCE OF CAD IN RELATION WITH 
METABOLIC SYNDROME AMONG TYPE2 DIABETICS 
METABOLIC 
SYNDROME 
NO. OF CASES 
WITH CAD 
(n=23) 
NO. OF CASES 
WITHOUT 
CAD (n=47) 
TOTAL 
PRESENT 20(86.95%) 29 (61.70%) 49 
ABSENT 03 (13.04%) 18 (38.29%) 21 
TOTAL 23 47 70 
 Out of 23 patients with evidence of CAD, 20 patients had 
metabolic syndrome (86.95%). 
 By applying chi-square test, there was a statistically significant 
association (P<0.05) between Metabolic syndrome and occurrence of 
CAD. 
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TABLE – 6  
ASSOCIATION BETWEEN HYPERTENSION AND CAD IN 
TYPE2 DIABETICS 
HYPERTENSION 
NO. OF 
CASES WITH 
CAD 
NO. OF 
CASES 
WITHOUT 
CAD 
TOTAL 
PRESENT 16 (44.44%) 20 (55.55%) 36 
ABSENT 07 (20.58%) 27 (79.41%) 34 
TOTAL 23 47 70 
 44.44% of Hypertension patients had CAD. By applying chi-
square test (X2=4.6 P<0.05) there was a statistically significant 
association between hypertension and occurrence of CAD 
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TABLE – 7  
ASSOCIATION BETWEEN RAISED LDL AND CAD IN 
TYPE2 DIABETES 
LDL > 100 mg% PATIENTS 
WITH CAD 
PATIENTS 
WITHOUT 
CAD 
TOTAL 
PRESENT 16 20 36 
ABSENT 07 27 34 
TOTAL 23 47 70 
 By applying chi-square test, there was a statistically significant 
association (P value < 0.05 X2 was 4.6) between LDL and occurrence of 
CAD. 
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TABLE – 8  
ASSOCIATION BETWEEN OBESITY AND CAD IN TYPE2 DM 
OBESITY 
NO. OF 
CASES WITH 
CAD 
NO. OF 
CASES 
WITHOUT 
CAD 
TOTAL 
PRESENT 20 (86.95%) 29 (61.70%) 49 
ABSENT 3 (13.04%) 18 (38.29%) 21 
TOTAL 23 47 70 
 Out of 23 patients with CAD, 20 patients were obese (waist 
circumference >80cm in females, >90cm in males). 
 By applying chi-square test, there was a statistically significant 
association (X2=4.77 P value < 0.05) between obesity and occurrence of 
CAD. 
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TABLE – 9  
ASSOCIATION BETWEEN INCREASED TRIGLYCERIDES 
AND CAD AMONG TYPE2 DIABETICS 
TGL≥150mg% PATIENTS 
WITH CAD 
PATIENTS 
WITHOUT 
CAD 
TOTAL 
PRESENT 16 21 37 
ABSENT 7 26 33 
TOTAL 23 47 70 
 By applying chi-square test, there was a statistically significant 
association (X2=3.91, P value <0.05) between TGL and occurrence of 
CAD. 
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TABLE – 10 
ASSOCIATION BETWEEN LOW HDL AND CAD AMONG 
TYPE2 DIABETICS (IN MALES <40; IN FEMALES <50) 
↓HDL PATIENTS 
WITH CAD 
PATIENTS 
WITHOUT 
CAD 
TOTAL 
PRESENT 13 9 22 
ABSENT 10 38 48 
TOTAL 23 47 70 
 By applying chi-square test, the x2 was 10.2 and P value was thus 
<0.005 – A statistically significant association exists between low HDL 
and CAD. 
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TABLE – 11  
PREVALENCE OF METABOLIC SYNDROME AMONG 
NON-DIABETICS 
METABOLIC SYNDROME NO. OF CASES PERCENTAGE
PRESENT 15 30% 
ABSENT 35 70% 
TOTAL 50 100% 
 Out of total 50 Non-Diabetic individuals, Metabolic syndrome 
was seen in 15 cases (30%) thus prevalence of Metabolic syndrome 
among Non-Diabetics was 30%. 
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TABLE – 12  
SEX DISTRIBUTION OF METABOLIC SYNDROME 
AMONG NON-DIABETICS 
METABOLIC SYNDROME MALE FEMALE 
PRESENT 8 (28.57%) 7 (31.81%) 
ABSENT 20 (71.42%) 15 (68.18%) 
TOTAL 28 22 
 Out of 28 male non-Diabetics, 8 persons had Metabolic syndrome 
(28.57%). 
 Out of 22 female non-Diabetics, 7 persons had metabolic 
syndrome (31.81%). 
 There is no much difference between the two groups. 
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TABLE – 13 
AGE DISTRIBUTION OF METABOLIC SYNDROME 
AMONG NON-DIABETICS 
METABOLIC SYNDROME 
AGE-GROUP 
PRESENT ABSENT 
TOTAL 
40-50 3 (13.04%) 20 (86.95%) 23 
51-60 5 (33.33%) 10 (66.66%) 15 
≥ 61 7 (58.33%) 5 (41.66%) 12 
In individuals between 40 and 50 years metabolic syndrome is 
present in 13.04% 
 In individuals between 51 and 60 yrs, metabolic syndrome is 
present in 33.33%. 
 In individuals ≥ 61 yrs, it is present in 58.33%. 
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TABLE – 14  
PREVALENCE OF CAD IN RELATION WITH 
METABOLIC SYNDROME AMONG NON-DIABETICS 
METABOLIC 
SYNDROME 
NO. OF 
CASES WITH 
CAD 
NO. OF 
CASES 
WITHOUT 
CAD 
TOTAL 
PRESENT 4 11 15 
ABSENT 1 34 35 
TOTAL 5 45 50 
 Out of 5 patients with evidence of CAD, 4 patients had metabolic 
syndrome. 
 By applying chi-square test, there was a statistically significant 
association (X2=6.53, P value <0.02) between metabolic syndrome and 
occurrence of CAD. 
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TABLE – 15  
ASSOCIATION BETWEEN IMPAIRED FASTING 
GLUCOSE AND CAD AMONG NON-DIABETICS 
IMPAIRED 
FASTING 
GLUCOSE 
NO. OF 
CASES WITH 
CAD 
NO. OF 
CASES 
WITHOUT 
CAD 
TOTAL 
PRESENT 3 9 12 
ABSENT 2 36 38 
TOTAL 5 45 50 
 Out of 5 patients with CAD, 3 of them had Impaired fasting 
glucose. 
 By applying chi-square test, there was a statistically significant 
association between CAD occurrence and Impaired fasting glucose. 
 X2=3.89, P value < 0.05 
3 2
9
36
0
5
10
15
20
25
30
35
40
PRESENT ABSENT
Impaired fasting glucose
N
o.
 o
f p
at
ie
nt
s
NO. OF CASES WITH CAD
NO. OF CASES WITHOUT CAD
 
 43
TABLE – 16  
ASSOCIATION BETWEEN OBESITY AND CAD AMONG 
NON-DIABETICS 
 Here obesity is defined as waist circumference >90cm (in 
males) >80 cm (in females). 
OBESITY 
NO. OF 
CASES WITH 
CAD 
NO. OF 
CASES 
WITHOUT 
CAD 
TOTAL 
PRESENT 4 16 20 
ABSENT 1 29 30 
TOTAL 5 45 50 
 Among 5 patients with CAD, 4 of them were obese. By applying 
chi-square test, there was no statistically significant association between 
central obesity and CAD occurrence among Non-Diabetics 
 (x2 was 3.69; P value between 0.1 and 0.05). 
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TABLE – 17  
ASSOCIATION BETWEEN RAISED TRIGLYCERIDES 
AND CAD AMONG NON-DIABETICS 
RAISED 
TRIGLYCERIDES 
NO. OF 
CASES 
WITH CAD 
NO. OF 
CASES 
WITHOUT 
CAD 
TOTAL 
PRESENT 4 6 10 
ABSENT 1 39 40 
TOTAL 5 45 50 
 By applying chi-square test there was a statistically significant 
association between Raised triglycerides and CAD among Non-
Diabetics. 
 (x2=12.5; P value <0.001) 
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TABLE – 18  
ASSOCIATION BETWEEN LOW HDL AND CAD 
OCCURENCE IN NON-DIABETICS 
LOW HDL 
NO. OF 
CASES WITH 
CAD 
NO. OF 
CASES 
WITHOUT 
CAD 
TOTAL 
PRESENT 3 - 3 
ABSENT 2 45 47 
TOTAL 5 45 50 
 By applying chi-square test, there was a statistically significant 
association between low HDL and occurrence of CAD among Non-
Diabetics. 
 (x2=28.72; P Value <0.001) 
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TABLE – 19  
ASSOCIATION BETWEEN RAISED LDL AND CAD 
OCCURRENCE AMONG NON-DIABETICS 
RAISED LDL 
NO. OF 
CASES WITH 
CAD 
NO. OF 
CASES 
WITHOUT 
CAD 
TOTAL 
PRESENT 1 2 3 
ABSENT 4 43 47 
TOTAL 5 45 50 
 By applying chi-square test there was no statistically significant 
association between CAD occurrence and raised LDL among Non-
Diabetics. 
 (x2=1.92, P value between 0.5 and 0.1) 
1
4
2
43
0
5
10
15
20
25
30
35
40
45
50
PRESENT ABSENT
RAISED LDL
N
o.
 o
f p
at
ie
nt
s
NO. OF CASES WITH CAD
NO. OF CASES WITHOUT CAD
 
 47
TABLE – 20  
ASSOCIATION BETWEEN HYPERTENSION AND CAD 
AMONG NON-DIABETICS 
HYPERTENSION 
NO. OF 
CASES WITH 
CAD 
NO. OF 
CASES 
WITHOUT 
CAD 
TOTAL 
PRESENT 3 4 7 
ABSENT 2 41 43 
TOTAL 5 45 50 
 Hypertension is defined as systolic BP≥140 and diastolic BP 
≥90(JNC, VII Classification). Though systolic BP≥130 and Diastolic 
BP≥85 is considered a component of Metabolic syndrome, we 
considered only patients with BP≥ 
90
140  as hypertensives under this 
section. 
 Among 5 persons with CAD, 3 of them were hypertensives. By 
applying chi-square, test, there was a statistically significant association 
between CAD and Hypertension among Non-Diabetics. X2=9.69;               
P Value <0.005 
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DISCUSSION 
 
 Out of 120 individuals who were taken up for final statistical 
analysis, the prevalence of metabolic syndrome among type 2 Diabetics 
was 70% and among Non-Diabetics was 30%. 
 A recent population based study by Isomaa and coworkers in 
finland [35] and Sweden concluded that metabolic syndrome was found 
in 80% of subjects with Type2 Diabetics and 10-20% of Normal 
subjects. Another study by Groop L and Orho-Melander [36] which 
defined metabolic syndrome according to WHO criteria also had similar 
results. The prevalence has varied in other studies eg., Bruneck study 
[37] because of lack of accepted criteria for the definition of the 
syndrome. 
 Out of 45 male Diabetics the syndrome was present in 32 males-
71.11%, in our study. 
 Out of 25 female diabetics the syndrome was present in 17 
females-68%, in our study. 
 In the Italian longitudinal study on ageing [38] the prevalence of 
metabolic syndrome was 64.9% in Diabetic males and 87.1% in diabetic 
females.  
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In our study out of 28 male non-diabetics 8 persons had 
metabolic syndrome ie., 28.57%. out of 22 female non-diabetics, 7 
persons had metabolic syndrome ie., 31.81%. This was 25.9% in non-
diabetic men and 55.2% in Non-diabetic women in the Italian 
longitudinal study on Ageing. Thus the result of our study is consistent 
with the findings of other studies mentioned. When distributed in 
accordance with age, among diabetics in our study, metabolic syndrome 
was present in 61.11% of patients aged 40-50 years. 71.42% of patients 
aged 51-60 yrs; 76.47% of patients >61 yrs of age. 
The same, among Non-diabetics was  
13.04% in patients between 40-50 yrs. 
 33.33% in patients between 51-60 yrs 
 58.33% in patients ≥ 61 yrs 
The increase in prevalence in metabolic syndrome was thus found with 
increasing age. This finding of our study was similar to the findings of 
Isomaa et al [35] and groop L and orho-melander [36] 
 Out of 53 patients with poor glycaemic control, CAD was found 
in 20 patients (37.73%). And out of 17 patients with good glycaemic 
control CAD was found in 3 patients (17.64%). 
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 Although there appears to be increased risk of CAD in patients 
with poor glycaemic control, by applying chi-square test, it was found 
that there was no statistically significant association (P value >0.05) 
between risk of CAD and glycaemic control. 
 Thus in our study, it was found that chronic hyperglycaemia has 
little effect on macrovascular complications of Diabetes mellitus. This 
finding of our study is similar to that of UKPDS [18] which showed that 
improved glycaemic control did not conclusively reduce cardiovascular 
complications and mortality. This shows that along with 
hyperglycaemia, other factors like, Dyslipidemia, hypertension play a 
role in the occurrence of CAD. 
 In DCCT [39] the number of cardiovascular events did not differ 
between the standard and intensively treated groups. This may be 
because the duration of diabetes in the subjects included in this study 
was relatively short and the total number of events was very low. 
 In our study, among diabetics, out of 23 patients with evidence of 
CAD 20 patients (86.95%) had metabolic syndrome. By applying chi-
square test, there was a statistically significant association (P<0.05) 
between metabolic syndrome and occurrence of CAD. Among non-
Diabetics, out of 5 patients with evidence of CAD, 4 had metabolic 
syndrome, the P value was <0.02, statistically significant. This finding 
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of our study in similar with that of Isomaa et al [35] and Fagan TC et al 
[40]. 
 Among Diabetics, there was a statistically significant association 
between hypertension and occurrence of CAD (P<0.05). And among 
non-diabetics also, the association between hypertension and CAD was 
statistically significant. 
 As far as obesity is concerned, there was a statistically significant 
association between obesity and CAD among diabetics and no such 
association in non-Diabetics. 
 This is because the association of obesity with cardiovascular 
disease is not direct: there is a strong etiologic association between 
obesity and other cardiovascular risk factors, especially for Diabetes; 
upto 75% of patients with type 2 Diabetes are reported to be obese. 
Therefore the association of obesity and CAD among diabetics would 
have been influenced by the underlying diabetic state itself. 
 Considering an association between increased TGL and CAD, it 
has a statistically significant association among both Diabetics and Non-
Diabetics-especially in Non-diabetics the association is very strong (P 
Value <0.001) HDL has a strong correlation with CAD occurrence in 
both Diabetics (P value <0.005) and Non-diabetics (P Value <0.001). 
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 Several large prospective observational studies showed that 
hypertriglyceridemia is an independent risk factor for CAD when it is 
associated with low HDL and /or raised LDL [31]. 
 In prospective studies in which triglyceride has been considered 
jointly with HDL-C, LDL-C, total cholesterol and other known CAD 
risk factors, multivariate statistical analysis generally have not shown 
TGL to be an independent risk factor for CAD [41]. 
 Because of a strong inverse correlation between TGL and HDL-
C, relatively low precision of TGL measurements and considerably 
higher variability of TGL values compared with cholesterol values, and 
finally very high TGL levels such as those with lipoprotein phenotype I 
and V appear to have no increased risk of CAD, the role of TGL as a 
marker of CAD has been diminished. 
 This is what shown in our study where HDL is proved to be a 
better marker of CAD among both diabetics and non-diabetics. 
 In one study [42] high TGL was associated with higher social 
classes compared to lower social class-4. Whereas HDL levels showed 
no association with social class. This probably could explain why HDL 
levels show stronger correlation with CAD occurrence than TGL levels 
in our study which was done in lower social class mainly. 
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 Among 19 prospective epidemiologic studies, 15 have shown a 
significant and strong inverse relationship between HDL-C and CAD, 
with a 2-3% decrease in CAD risk for each 1 mg/dl increase in HDL-C 
level, after adjustment to control for other risk factors.[4] 
 Association between IFG and CAD was tested in Non-diabetics 
and it showed a strong statistically significant association (P value 
<0.05). We never tested this component of metabolic syndrome among 
diabetics because almost 64 of 70 diabetics had fasting glucose >110 mg 
and Diabetes itself is CAD equivalent.  
 Testing IFG and CAD correlation shows that it is possible that 
much lower levels of fasting hyperglycemia may be associated with 
CAD and other microvascular complications than the level currently 
used for the diagnosis of Type 2 D.M. (126 mg/dl) 
 There was a statistically significant association between raised 
LDL and CAD among diabetics (P value <0.05) but among Non-
diabetics the association failed (P value between 0.5 and 0.1) suggesting 
that LDL-C, as an independent risk factor of CAD, has failed… whereas 
as a component of Dyslipidemia (↑TGL, ↓ HDL and ↑ LDL) is a 
definite risk factor. 
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LIMITATIONS OF THE STUDY 
1. Measurement of a single fasting Triglyceride may inadequately 
represent this lipid. Post-prandial TGL level is a better index of 
CAD risk than fasting value. [43] 
2. Lp (a) levels were not measured which is 10 times more 
atherogenic than LDL. Levels >30 mg/dl are associated with a 
two fold greater risk for CAD and this is regardless of the 
absolute level of LDL. 
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SUMMARY AND CONCLUSIONS 
1. (a) The prevalence of metabolic syndrome among Type 2 Diabetics 
in our study is 70%. 
(b) The prevalence of metabolic syndrome among non-Diabetics is 
30% 
2. There was no significant difference found in prevalence of metabolic 
syndrome in males and females among both Diabetics and non-
Diabetics. 
3. There was a clear increase in prevalence of metabolic syndrome 
found with increasing age in both the study population. 
4. No statistically significant association between glycaemic control 
and CAD occurrence. 
5. A Statistically significant association was found between MS and 
CAD among Diabetics and Non-Diabetics. 
6. Among all the components of Metabolic syndrome low HDL was 
found to be the strong predictor of CAD in both the study population. 
Thus it is concluded that: 
1. Presence of metabolic syndrome influences risk of CAD among 
both Diabetics and Non-diabetics. 
2. HDL can be used as a surrogate marker for CAD occurrence  
among diabetics and general population. 
  
 
ABBREVIATIONS 
 
1. CAD - Coronary Artery Disease 
2. WHO - World health organisation 
3. NCEP - National cholesterol education programme 
4. ATP-III - Adult treatment panel 
5. HDL - High density lipoprotein 
6. LDL - Low density lipoprotein 
7. LP (a) - Lipoprotein (a) 
8. TGL - Triglycerides 
9. BP - Blood Pressure 
10. IFG - Impaired fasting glucose 
11. TGT - Impaired glucose tolerance 
12. ACE-I - Angiotensin converting enzyme-Inhibitor 
  
13. ARB - Angiotensin Receptor Blocker 
14. eg., - example 
15. DM - Diabetes Mellitus 
16. HB A1C- Hemoglobin A1 C 
17. esp. - especially 
18. MI - Myocardial Infarction 
19. OPD - Out patient Department 
20. ADA - American Diabetes Association 
21. S.No - Serial Number 
22. H/O - History of  
23. M.S - Metabolic Syndrome  
24. E/O - Evidence of   
  
A CORRELATIVE STUDY OF METABOLIC 
SYNDROME AND CAD AMONG TYPE 2 
DIABETICS AND NON DIABETICS – 
PROFORMA 
Name …………………………………………………………………… 
Age …………………………….. Sex ………………………………… 
Address ………………………………………………………………..  
…………………………………………………………………………… 
Occupation …………………………………………………………… 
Roll Number …………………………………………………………. 
Family History of DM ………………………………….  Yes      No 
Family history of CAD …………………………………. Yes       No 
Exclusion criteria history of smoking ……………… Yes      No 
Exclusion criteria history of Alcohol consumption. Yes      No 
Does the patient have diabetes……………………….. Yes      No 
History of CAD……………………………………………. Yes      No 
History of hypertension ……………………………….. Yes      No 
History of stroke…………………………………………. Yes      No 
Long term ongoing Treatment if any ………………………………….. 
  
Physical Examination 
Ht……………………………….. Wt………………………………………… 
Waist Measurement ………………………………………………………. 
BP …………………………………………………………………………….. 
Investigations 
Fasting Blood glucose ……………………………………………………. 
Serum Triglycerides ………………………………………………………. 
Serum HDL Cholesterol …………………………………………………. 
Serum LDL Cholesterol …………………………………………………. 
ECG ………………………………………………………………………….. 
ECHO ………………………………………………………………………… 
 ………………………………………………………………………………… 
HbA1 C ……………………………………………………………………… 
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